Humaneva, a NEUCA Spin-Off, Receives Significant US Private Equity Backing for Further Clinical Research Market Consolidation and Global Expansion

On September 24, the Board of Directors of NEUCA S.A. signed a significant investment agreement with Viking Global Investors, a global investment firm based in the United States (“Viking”). Under this agreement, Viking acquired a minority stake in Humaneva Inc., a spin-off of NEUCA S.A., for $50M. In addition, Viking has been granted a one-year option to invest an additional $50M in Humaneva Inc. The transaction will contribute to the implementation of the long-term strategy in the area of clinical trials. In the personnel area, in the second quarter this year, Bartosz Józefiak (among others, former CFO of Benefit Systems) joined the Humaneva Inc. team as a member of the Board of Directors responsible for Finance. 

Humaneva Inc., the parent company of Pratia, Kapadi, and Hyggio—leaders in providing integrated clinical trial solutions—aims to accelerate the evolution of its business model. As a prominent player in the European market, the Group is now setting its sights on expanding into the American and APAC regions, both recognized as hubs for advanced clinical trial activities. With over 90 dedicated and integrated Clinical Trial Centers, Humaneva plans to strengthen its proprietary technology offerings, focusing on eSource solutions, data integration, and analytics, with the goal of broadening access to clinical research as a care option worldwide. 

- The clinical trials market is undergoing rapid transformation, driven by global consolidation and innovative business models. Partnering with Viking is a strategic milestone for us. Viking’s unique blend of hedge fund and private equity expertise, coupled with their long-term, value-building perspective, aligns perfectly with Humaneva's vision, said Tomek Dabrowski, CEO of Humaneva Inc. The United States accounts for nearly 80% of all R&D expenditures in the clinical trials market. Strengthening our presence, especially in the US, will significantly expand our scale and capabilities in the coming years. 

Humaneva distinguishes itself through its direct patient access, strong oncology focus, advanced data management capabilities, and proprietary technology that seamlessly integrates clinical trial centers, sponsors, and CROs. This innovative approach enhances project efficiency by streamlining processes, reducing indirect tasks that can impact time, quality, and data consistency. As a result, trial sponsors benefit from reduced costs associated with molecule development, ensuring a faster and more efficient path to market. 

- In addition to the financial aspect related to obtaining funds for the development of the clinical trials segment in the NEUCA Group, cooperation with our new partner may result in prospective new contacts and greater trust in our company from the American market players. This transaction is also a proof of the high potential of this area and thus of the long-term prospects of the Group as well as the credibility of our activities and confirms the correctness of the growth trajectory for the segment pursued so far. We believe that together with Viking we will effectively build value for the shareholders of Humaneva, and thus for the NEUCA Group – says Grzegorz Dzik, Vice President of the Board of Directors of NEUCA S.A.